GlassScriptPhysician profile
Andrew J Morpurgo
NPI 1326021023
$3,148.09
in general payments reported to CMS, 2019-2025
21 companies · $714 in 2025
The $714 reported for 2025 was more than what 84% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $611 · 2020: $401 · 2021: $614 · 2022: $227 · 2023: $228 · 2024: $353 · 2025: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,295.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $1,169.25 | 2019-2025 | Xtampza, Belbuca |
| Daiichi Sankyo INC. | $415.20 | 2019 | |
| Pfizer INC. | $211.39 | 2020-2021 | |
| Spr Therapeutics, INC | $201.83 | 2025 | Sprint Pns System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $171.56 | 2020-2022 | |
| Biodelivery Sciences International, INC. | $160.28 | 2019-2021 | |
| Vertex Pharmaceuticals Incorporated | $148.53 | 2024-2025 | |
| Biohaven Pharmaceuticals, INC. | $125.00 | 2021 | |
| Nevro Corp. | $110.14 | 2019-2022 | |
| Averitas Pharma INC. | $76.64 | 2025 | Qutenza |
| Tonix Medicines, INC. | $67.35 | 2025 | Tonmya |
| Boston Scientific Corporation | $65.47 | 2022-2023 | Wavewriter Alpha Prime 16 |
| Scilex Pharmaceuticals INC. | $43.12 | 2019 | |
| Medtronic, INC. | $40.79 | 2024 | Intellis Adaptivestim |
| Biohaven Pharmaceutical Holding Company LTD. | $26.11 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $23.41 | 2019 | |
| Abbott Laboratories | $23.10 | 2023 | Eterna |
| Avanos Medical | $18.50 | 2020 | |
| Abbvie INC. | $17.95 | 2023 | |
| Vertos Medical, INC. | $17.82 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Morpurgo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.